ANGO — Angiodynamics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Angiodynamics, fiscal year end - May 31st, USD millions except per share, conversion factor applied.

	2020 May 31st	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	8-K
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	264	291	316	339	304
Cost of Revenue
Gross Profit	150	157	166	174	155
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	431	326	345	390	496
Operating Profit	-167	-35.3	-28.5	-51.2	-192
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-168	-36.1	-29.9	-54.4	-192
Provision for Income Taxes
Net Income After Taxes	-167	-31.5	-26.5	-52.4	-184
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-167	-31.5	-26.5	-52.4	-184
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-167	-31.5	-26.5	-52.4	-184
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.58	-0.48	-0.53	-0.831	-2.03